Войти в систему Зарегистрироваться бесплатно

RepliCel Life Sciences Доход

Что обозначает Доход в RepliCel Life Sciences?

Доход RepliCel Life Sciences, Inc. является -CAD$371.00

Какое определение для Доход?

Чистая прибыль, подлежащая распределению среди обычных акционеров, равна чистой прибыли за вычетом выплаченных привилегированных дивидендов.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Доход компаний в Health Care сектор на TSXV по сравнению с RepliCel Life Sciences

Что делает RepliCel Life Sciences?

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

Компании с доход похож на RepliCel Life Sciences